TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and

TellBio, Inc., a biotechnology company specializing in cancer detection, has recently published two manuscripts that highlight the potential applications of its TellDx platform in prostate cancer and advanced breast cancer. The papers, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cul..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 10.
  • textsms

TellBio Announces Consecutive Manuscripts Demonstrating Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Advanced Breast Cancer

TellBio, Inc., a biotechnology company focused on cancer detection, has recently published two manuscripts that highlight the applications of its TellDx platform in prostate cancer and advanced breast cancer. The publications, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cultured ful..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech, a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its PCA001 clinical trial. The study is designed to determine the efficacy and safety of VTP-850 monotherapy in men with rising PSA after definitive local therapy for prostate cancer. VTP-850 is a next-generation immunotherapeutic candidate that uses two proprietary non-replicating viral vecto..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms